Bradford Dahms serves as Chief Financial Officer at JADE BIOSCIENCES INC., where he oversees all financial operations, strategic planning, and investor relations for the innovative biotechnology company focused on advancing therapies for rare diseases. With over 20 years of experience in the biotech and pharmaceutical sectors, Dahms brings a proven track record of driving financial growth and operational efficiency. He holds an MBA from the Wharton School of the University of Pennsylvania and a Bachelor's degree in Accounting from the University of California, Berkeley, and is a Certified Public Accountant (CPA). Prior to joining JADE BIOSCIENCES, Dahms held senior finance roles at leading biotech firms, including Vice President of Finance at Genentech, where he spearheaded a $500 million Series C funding round that accelerated clinical trials for oncology drugs. His achievements also include optimizing capital structures during mergers and acquisitions, resulting in a 35% increase in shareholder value at his previous employer, BioVantage Therapeutics. Dahms has been instrumental in navigating complex regulatory landscapes and securing non-dilutive funding from government grants, amassing over $1.2 billion in total capital raised throughout his career. At JADE BIOSCIENCES, Dahms plays a pivotal role in positioning the company for sustainable growth amid rapid R&D expansion. He leads budgeting for multi-phase clinical programs, implements robust risk management frameworks, and fosters partnerships with venture capital firms and strategic investors. Under his leadership, the company has achieved key financial milestones, including positive cash flow from operations and preparation for an upcoming IPO, solidifying JADE's trajectory as a leader in precision medicine.